Last $672.60 MXN
Change Today 0.00 / 0.00%
Volume 0.0
SNYN On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 4:09 PM 08/14/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Open
$672.60
Previous Close
$672.60
Day High
$672.60
Day Low
$672.60
52 Week High
05/5/14 - $710.59
52 Week Low
02/6/14 - $626.75
Market Cap
1.8T
Average Volume 10 Days
7.3
EPS TTM
--
Shares Outstanding
2.6B
EX-Date
05/7/14
P/E TM
--
Dividend
$1.89
Dividend Yield
3.69%
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., and Medtronic, Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi-adr (SNYN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi-adr (SNYN) Key Developments

Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology

Illumina, Inc. announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi. Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners' clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.

Sanofi Launches Authorized Generic Version of Eloxatin

Sanofi US announced that it has launched an authorized generic version of Eloxatin(R) (oxaliplatin injection) through Winthrop US. Sanofi's authorized generic version is the same formulation as the original drug, Eloxatin, for which the company holds the original patent. Eloxatin is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin. This treatment is indicated for treatment of advanced colorectal cancer or as adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. The authorized generic version of Eloxatin will be available in the same sizes, 50 mg and 100 mg single-use vials.

Sanofi and MannKind Partner to Develop and Commercialise Afrezza to Treat Diabetes

Sanofi and MannKind have signed an exclusive licensing agreement to develop and commercialise Afrezza (insulin human) inhalation powder. Afrezza is a new rapid-acting inhaled insulin therapy developed to treat adults with type I and type II diabetes. As part of the deal, both firms plan to introduce Afrezza in the US in the first quarter of 2015. Sanofi will undertake global commercial, regulatory and development activities of Afrezza, while MannKind will manufacture Afrezza at its production facility in Danbury, Connecticut, US under a separate supply agreement. The firms are also planning to collaborate to expand their manufacturing capacity to meet global demand. Based on the terms of the agreement, MannKind will receive an upfront payment of $150 million and potential milestone payments of up to $775 million. Sanofi has agreed to provide its share of the collaboration's expenses up to a limit of $175 million to MannKind.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $672.60 MXN 0.00

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $132.53 USD -0.15
Bayer AG €99.59 EUR -0.27
Gilead Sciences Inc $102.27 USD +1.48
GlaxoSmithKline PLC 1,427 GBp -8.00
Merck & Co Inc $58.85 USD -0.63
View Industry Companies
 

Industry Analysis

SNYN

Industry Average

Valuation SNYN Industry Range
Price/Earnings 24.8x
Price/Sales 3.0x
Price/Book 2.0x
Price/Cash Flow 14.9x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.